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Summary
Objective: The efficacy of glucosamine sulfate (GS) in the symptomatic treatment of patients with osteoarthritis (OA) is suggested to be
mediated by still unknown effects on the altered OA cartilage.
Design: Using human OA chondrocytes in culture, the effects of GS on protein synthesis, caseinase, collagenase, phospholipase A2 (PLA2)
and protein kinase C (PKC) activities as well as production of nitric oxide and cyclic AMP were studied in both cells and culture medium.
Results: GS significantly reduced PLA2 activity, and more modestly collagenase activity, in the OA chondrocytes in a dose-dependent
manner. By contrast, PLA2 and collagenase activity of the culture medium was not modified. No effects on caseinase activity was seen. GS
significantly and dose-dependently increased protein synthesis. GS did not modify nitric oxide and cAMP production but significantly
increased PKC production.
Conclusion: GS modified cultured OA chondrocyte metabolism by acting on PKC, cellular PLA2, protein synthesis and possibly collagenase
activation. Extrapolation of the effect to the in-vivo situation remains hypothetical but they might represent some possible mechanisms of
action of the drug in human. © 2000 OsteoArthritis Research Society International
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Glucosamine sulfate (GS) is the salt of the natural amino-
monosaccharide glucosamine which is physiologically
present in the human body. Glucosamine plays an import-
ant role in the biochemistry of cartilage as it is a fundamen-
tal molecule for the synthesis of glycosaminoglycans and
hyaluronic acid which form together the large aggragating
proteoglycans characteristic of this tissue. In clinical trials
GS has been proven to modify symptoms in osteoarthritis
(OA)1–3 and therefore GS is classified as symptom-
modifying drug in OA according to OARS4 and GREES5
recommendations. Recently, GS has also been found to
significantly reduce progression of joint-space narrowing in
patients with knee OA and suggested GS to be a possible
disease-modifying agent.6 As the reduction of OA symp-
toms by GS is not due to inhibition of prostaglandin
synthesis,7 other mechanisms of action must be respon-
sible for the specific action of GS in decreasing pain and
limitation of joint movement. One hypothesis is that GS has
a beneficial influence on OA chondrocyte activities resulting
in less degradation of cartilage. Normalization and stabil-
ization of articular cartilage metabolism could lead to fewer
beakdown products, less irritation and inflammation of the207synovial tissue and therefore improved symptoms. As well
as this hypothesis, other reasons for symptom reduction by
GS are possible. A better understanding of the cellular
effects of GS may uncover a new mechanism of action.
Numerous biochemical and metabolical changes have
been identified in OA cartilage. Proteoglycan loss and a
loosening of the collagen network,8 possibly mediated by
both an increased matrix degradation by metalloprotein-
ases9,10,11 and by a decreased matrix synthesis12,13 are
now well documented. OA chondrocyte dysregulation is
also demonstrated by several changes such as an
increased level of receptors to some cytokines,14,15 and
an increased production of phopholipase A216 and nitric
oxide.17,18
In early pharmacological studies it was shown that C14
labelled glucosamine enters into the biosynthesis of glycos-
aminoglycans and therefore stimulates proteoglycan syn-
thesis.19 In vitro, this effect was demonstrated in cultured
human chondrocytes derived from osteoarthritic cartilage.
GS added to the culture medium stimulates chondrocytes
to synthesize increased amounts of proteoglycans in a
dose-dependent manner.20 This finding was recently con-
firmed employing molecular biology.21 In the present
study, cultures of human OA chondrocytes were used to
determine the effects of GS on protein synthesis and on
caseinase, collagenase and phospholipase A2 (PLA2)
activities. Additional studies to determine its effect on the
production of nitric oxide and cyclic AMP as well as the
level of protein kinase C were also conducted to elucidate
possible mechanisms of action of GS on OA chondrocytes.
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GLUCOSAMINE SULFATE
GS was provided by Rotta Research Laboratorium
(Monza, Italy) and used in the culture medium at
concentrations of 0 (control), 5, 50, 100 and 500 M.CHONDROCYTE CULTURE
Knee joints from patients with medial femoro-tibial OA
were obtained at the time of joint replacement. A total of 18
knees were used. Specimens were washed with sterile cold
physiological saline and kept for 12 hours at 4°C in Gey’s
saline solution (Gibco, Life Technologies, Cergy-Pontoise,
France). Non-osteophytic fibrillated cartilage from medial
femoral condyles was dissected and cut in approximately
1-mm3 fragments in the Gey’s solution.
Chondrocytes were isolated at 37°C by sequential enzy-
matic digestion with 0.2% trypsin (Gibco) for 30 min and
then for 6 hours with 0.2% collagenase (Sigma, type IV) in
Gey’s solution as previously reported.22 Cells were
obtained after filtration with a Blutex 82  filter and centrifu-
gation at 1100 g for 5 min at 4°C. The pellet was then
suspended in Gey’s solution and the isolated cells were
counted using a Thomas’ cell. The cells were cultured at
high density (8×106/ml) in a liquid suspension of HAM’s
F12 medium (Gibco) containing 10% Ultroser (IBF,
Sepranor, Villeneuve la Garenne, France) and antibiotics
(Penicillin, 100,000 U/ml, streptomycin, 10 g/ml) in a 95%
air, 5% CO2 atmosphere at 37°C.ENZYME ACTIVITY ASSAYS
After 72 hours of culture the medium was removed and
the cells isolated by centrifugation (1100 g, 5 min). Aliquots
of the cells (4×106 cells/0.5 ml) were cultured for 24 hours
with various concentrations of GS as described above. The
cells were then collected by centrifugation (1100 g for
5 min) and sonically disrupted (Sonimas 25 T probe at 125
v, Annecy, France) with three 15-sec cycles in HAM’s F12
medium Tris-HCl 5×10−2 M pH 7.5.Determination of caseinase activity
Caseinase was determined as previously described.22
The incubation mixture contained: 200 l of cell homoge-
nate or culture medium, 30 l of buffer (Tris HCl 0.416 M,
pH 7.5, NaCl 1.25 M, CaCl2 0.083 M, NaN3 0.166%, Triton
X-100 0.83%) and 50 l of 0.5% casein fluorescein isothio-
cyanate. After incubation at 37°C for 24 hours, 280 l of 5%
trichloracetic was added. The precipitate was removed by
centrifugation. Two ml of Tris-HCl 0.50 M, pH 8.5 buffer
was added to 250 l of supernatant. Fluorescence was
determined using a fluorimeter at  Ex=365 nm and 
Em=525 nm and expressed in units of fluorescence per
hour of incubation and per mg of protein. Assays of protein
23were performed as reported previously.Determination of collagenase activity
The assay used digestion of 3H-labeled type II collagen
(Bioethica, Lyon, France), as previously reported.24 The
incubation mixture contained: 200 l of cell homogenate or
culture medium, 30 l of 0.42 M Tris-HCl buffer, pH 7.5[1.25 M NaCl, 0.083 M CaCl2, 0.66% (w/v) sodium azide
and 0.83% (w/v) Triton X-100 and 20 l of 3H acetyl-
collagen (about 100,000 dpm)]. After incubation at 35°C for
24 hours, the reaction was stopped by adding 100 l of
unlabeled collagen (1.5 mg/ml), 0.04 M EDTA and 350 l of
Dioxan. After centrifugation, the radioactivity of the super-
natant was determined. The spontaneous release of radio-
activity from 3H-labeled type II collagen was determined in
several blanks by incubating labeled type II collagen simi-
larly but in the absence of enzyme extracts. Casein and
collagen degradation was also studied with addition of
EDTA 10 mM or 1.10 phenantrolin 1 mM. A nearly complete
inhibition of both activities was observed with both the
treatments.Determination of phospholipase A2 (PLA2) activity
The assay was performed employing a previously
reported method,16 using unlabeled L--phosphatidyl-
ethanolamine and labeled 1-palmitoyl-2-(114C) linoleyl-L-3-
phosphatidyl-ethanolamine (Dupont, NEN, Les Ulis,
France) as substrates. Briefly, 100 nmol of substrate
(20,000 dpm), 3% sodium deoxycholate (50 l), 0.25 M
Tris-HCl buffer (200 l) pH 7.5, 0.1 M CaCl2 (50 l) and
200 l of culture medium or cell homogenate were incu-
bated for 4 h at 37°C. (14C)-linoleic acid was then extracted
with Dole’s reagent (isopropanol 40p., heptan 10p., H2SO4
0.5 M 1p.). Radioactivity was counted with 10 ml toluene-
based scintillation fluid (scintillation cocktail: POPOP 0.1 g/
l, PPO 5 g/l). PLA2 activity was calculated by substracting
the value at 0 min and the non enzymatic degradation of
the substrate measured in the samples. Results were
expressed as dpm per hour of incubation per mg of protein.Determination of protein synthesis
Protein synthesis measurement was based on the incor-
poration of 14C amino-acids (N.E.N) into macromolecules.
The incubation mixture contained: 200 l of cell homog-
enate, 10 l ATP (5 mM), 10 l MgCl2 (5 mM) and 10 l
50 mM Tris-HCl buffer pH 7.4. The reaction was initiated by
addition of 10 l 14C amino-acid mixture (20 pCi/ml). After
60 min at 37°C, the reaction was stopped by adding 4%
phosphotungstic acid/10% trichloracetic acid (PTA/TCA).
The precipitated macromolecules were filtered through
glass-fibre discs (Whatman GF/B). The precipitate was
washed with PTA/TCA. Filters were dried and their radio-
activity content was determined in a Tri-Carb Packard liquid
scintillation counter.Determination of nitric oxide, cyclic AMP and
protein kinase C
Chondrocytes were cultured for 72 h as described
above. Then, cells (4×106 cells/0.5 ml) were cultured with
GS as described above for 30 min for the assay of
3′5′cyclic adenosine monophosphate (cAMP) and for 48 h
for the measurement of nitric oxide (NO) or protein kinase
C (PKC) activity.NO production. NO was determined in the culture
medium supernatant by the measurement of nitrate and
nitrite release using the Griess reaction (1 volume of 1%
sulfanilamide, 1 volume of 0.1% in H PO naphtylethylene3 4
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standard solutions of sodium nitrite.PKC activity assay. The PKC activity of cells was
assayed by measuring the binding of radiolabeled phorbol
esters on total cell membrane PKC (2 moles of phorbol
binding 1 mole of PKC), according to the method of
Hannun et al.25 Phorbol esters only bind on tandem
motives made of six cysteinyl residues. PKC isoforms
(dzeta) lacking the sequence were undetected by the
assay. Chondrocytes were incubated for 30 min at 4°C in a
culture medium containing 10 nM of 3H phorbol 12,13
dibutyrate (3H-PDBu). The non-specific binding of (3H)-
PDBu was determined in parallel by saturating the sites
with 10 M of unlabeled PDBu. The reaction was stopped
by centrifugation and washing of cells (NaCl 150 nM, Tris
50 mM pH 7.4, BSA 2 mg/ml). The cells were then dis-
solved by adding 1 ml 0.5 N NaOH. The radioactivity of the
cell digests was measured by liquid scintillation. Results
were expressed in pM of bound (3H)-PDBu per mg of
protein.Cyclic AMP assay. Cyclic AMP of cell extracts was
measured using a radioimmunoassay after acetylation.26,27
Chondrocytes were lysed using a Potter homogenizer and
ultra-sound in presence of a phosphodiesterase inhibitor
(theophylline, 2 ng/ml). Proteins were then precipitated with
4 vol ethanol. After centrifugation, the supernatant was
evaporated to dryness under N and dissolved in a 0.05 M
phosphate buffer pH 6.2. Extracts (500 l) were mixed
successively and rapidly under agitation with 10 l of tri-
ethylamine and 5 l of acetic anhydride. Assay of cAMP
was made using a competitive reaction between a 125I-
cAMP-succinyl-tyrosine methyl ester and the cAMP to be
measured employing an anti-cAMP specific immune
serum. Results were expressed in pM of cAMP per 106
cells.STATISTICAL ANALYSIS
For each assay, aliquots of cells originating from only
one joint were used to evaluate the six concentrations of
GS (from 0 to 500 M) and samples from six different joints
were tested. Each assay for each concentration of GS was
made in triplicate and data were not selected. The differ-ences between groups of increasing GS concentration
were studied with an analysis of variance and a linear
regression analysis. For comparison of two groups a paired
test of Wilcoxon was used.ResultsEFFECT OF GS ON DEGRADATIVE ENZYMES
Enzyme activities were determined in chondrocytes from
grossly fibrillated cartilage from OA knees. The effect of
each concentration (0 to 500 M) of GS on one enzyme
activity was determined in triplicate using aliquots of cells
from one joint. Result for each enzyme activity was the
mean of six different experiments, each of them being
made with cells originating from only one patient (Table I).
Caseinase activity of either the cells or media was not
modified by GS. The drug did not modify collagenolytic
activity in the media but significantly (P<0.05) decreased
collagenolytic activity of the cells. The decrease was only
found with concentrations of 100 and 500 M [21%
(P<0.02) and 30% (P<0.02)], respectively. Similarly, GS did
not modify PLA2 activity in the culture media but signifi-
cantly (P<0.05) decreased the cellular PLA2. The values of
PLA2 were inversely and strongly correlated with GS
concentrations (r=0.78, P<0.0001). The minimum effective
concentration was 50 M (P<0.02). The decrease reached
62.4% with 500 M.EFFECT OF GS ON PROTEIN SYNTHESIS
Protein synthesis was significantly (P<0.05) increased
by GS. The increase was strongly correlated with the drug
concentration (r=0.65, P<0.001). The minimum effective
dose was 50 M (P<0.04). The increase reached 62.8%
with 500 M (Table I).Table I
Effect of glucosamine sulfate (GS) on protein synthesis and caseinolytic, collagenolytic and phospholipase A2
(PLA2) activity of human osteoarthritic chondrocytes in culture
GS (M)
0 5 50 100 500
Protein synthesis 2476±276 2485±310 2985±296* 3846±649* 4031±714*
Caseinase (medium) 1560±297 1590±390 1685±485 1690±317 1636±379
Caseinase (cells) 1296±194 1388±296 1351±311 1400±328 1141±232
Collagenase (medium) 4216±315 4368±463 4398±425 4271±350 4075±485
Collagenase (cells) 5588±874 5291±543 5468±419 4410±425* 3911±432*
PLA2 (medium) 690±101 772±116 723±125 710±149 606±137
PLA2 (cells) 1389±115 1176± 98 995± 75* 689± 83* 522± 89*
Cells were incubated with GS for 24 h, as described in Materials and Methods. Protein synthesis (incorporation
of radiolabeled amino-acids into macromolecules), collagenase and PLA2 activity are expressed in disinte-
grations per minute per hour of incubation and per milligram of protein. Caseinase is expressed in unit of
fluorescence per hour of incubation and mg of protein. The values shown are the mean±SD of six assays.
*P<0.05 (versus untreated samples).EFFECT OF GS ON NO, CAMP AND PKC
Results are shown in Table II. NO production by OA
chondrocytes was found to be unaffected by GS. In
addition, production of cAMP was not modified by GS. The
binding of 3H-PDBu on OA chondrocytes was not modified
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trations of 50, 100 and 500 M, GS significantly (P<0.05)
increased the binding of radiolabeled phorbol esters on the
regulating site of membrane PKC, by 65, 78.5 and 80.9%,
respectively.Discussion
Glucosamine sulfate was found to regulate several
important metabolic activities of OA chondrocytes in vitro.
GS significantly increased protein synthesis, in agreement
with other studies indicating both a stimulation of 3H-proline
uptake and an increase in proteoglycan synthesis.19,20,21
Since there is a reduction of aggrecan and type II collagen
mRNA levels, at least in the advanced stages of cartilage
destruction in OA cartilage, such a stimulation of matrix
synthesis could be of therapeutic importance.13
An excessive matrix degradation by metalloproteinases
is another characteristic of OA cartilage.9–11 Degradation of
casein and collagen was probably mainly due to metallo-
proteinase since both activities were abolished by EDTA or
phenantrolin. GS did not modify caseinolytic activity but
significantly decreased the collagenolytic activity associ-
ated with the cells. Collagenolytic activity was not
decreased in the culture medium suggesting GS had no
effect on enzyme synthesis. Thus, the drug probably acted
on the mechanisms inducing activation of the enzyme
proform during the cell manipulation. These results contrast
with the in-vitro effect of nonsteroidal antiinflammatory
drugs which induced the opposite effect.24 Inhibition of
collagenase appears to be of great importance in the
treatment of OA, since some collagenase inhibitors have
been shown to prevent cartilage destruction in experimen-
tal OA.28,29 Collagenase inhibition by GS, however, was
found to be relatively modest, although the drug was given
to the cell for a relatively short period of time. It is likely
that longer term incubation of OA chondrocytes with GS
may result in more substantial reduction in the levels of
collagenase activity.
Synthesis and release of soluble PLA2 has been
reported to be characteristic of chondrocytes.30 An
increase in PLA2 activity was found in OA cartilage,16 as
well as in the synovial fluid and serum of OA patients.31,32
PLA2 is known as a proinflammatory enzyme but its
precise role in OA remains largely unknown. It has been
shown that the inflammatory and cartilage catabolic effects
of interleukin-1(IL-1) in the rabbit joint were significantly
reduced by a potent inhibitor of PLA233 suggesting this
enzyme is responsible for mediating some of the effects of
IL-1 in OA. Cellular PLA2 has also been suggested to be a
possible activator of collagenase activity.34 In the presentstudy GS did not modify the production of soluble PLA2,
after the short period of treatment, but significantly
decreased cellular PLA2 activity. Thus, inhibition of PLA2
by GS could be expected to improve both the clinical
symptoms and progression of cartilage destruction in OA.
GS did not modify the content of cAMP within cells nor
decreased production of NO. NO has been shown to
mediate both the catabolic and antianabolic effects of IL-1
on cartilage.35 However, GS significantly increased PKC.
Activation of PKC was found to have no effect on proteo-
glycan synthesis by normal chondrocytes but was found
to inhibit the downregulation of proteoglycan synthesis
caused by IL-136 Thus, the GS induced increase in PKC
could be one mechanism responsible for the observed
increase in proteoglycan synthesis caused by GS.
In conclusion, the present work shows that GS exerts
several in vitro effects on OA chondrocytes. Statistically
significant effects of the drug were observed by using a
concentration of 50 M at least. Pharmacokinetic studies
with radiolabeled GS in humans showed that a level of
100 M glucosamine blood could be achieved after oral
administration of a therapeutic dose.37 The level resulted
from both free glucosamine and glucosamine incorporated
in plasma proteins while the free glucosamine serum level
was much lower. However, radiolabeled glucosamine was
also shown to concentrate in synovial fluid and and carti-
lage. Thus, extrapolation of in-vitro data to the in-vivo
situation is quite difficult and this work only suggests some
ways by which GS might affect the OA dysregulated
cartilage metabolism.Acknowledgments
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Effect of glucosamine sulfate (GS) on nitric oxide (NO), cyclic adenosine monophosphate (cAMP) and protein
kinase C (PKC) activity (binding of 3H-PDBU) of human osteoarthritic chondrocytes in culture
GS (M)
0 5 50 100 500
NO (mol of nitrites) 0.0413±0.009 0.0416±0.012 0.0436±0.014 0.044±0.016 0.0495±0.017
cAMP (pmoles) 7 ±5.6 9.02±6.62 8.16±5.10 9.75±5.85 8.85±6.02
PKC activity 0.236±0.096 0.268±0.059 0.676±0.217* 1.100±0.263* 1.238±0.323*
Cells were incubated with GS for 24 h, as described in Materials and Methods. NO and cAMP are expressed
per 106 cells. PKC activity is expressed in pmoles of bound 3H-PDBU per mg of protein.
The values shown are the mean±SD of six different assays. *P<0.05 (versus untreated samples).References
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